论文部分内容阅读
目的肿瘤睾丸抗原(cancer-testis antigens,CTAs)可限制性表达于睾丸生殖细胞及肿瘤细胞,并具有高免疫原性等特点,可激发肿瘤患者机体免疫应答,被认为是抗原特异性免疫治疗的潜在靶点。本实验分析和鉴定黑色素瘤优先表达抗原家族成员12(preferentially expressed antigen ofmelanoma family member 12,PRAMEF12)是否为一个新的肿瘤睾丸抗原,并探究其在肾癌组织中的表达。方法采用逆转录-聚合酶链反应(RT-PCR)分析PRAMEF12 mRNA在成人多器官正常组织及肾癌组织中的表达特点。蛋白印迹法(Western Blot)及免疫组织化学分析PRAMEF12蛋白在肾癌组织中的表达特点。运用统计学方法分析PRAMEF12蛋白的表达量和病例临床特点之间的关系。结果PRAMEF12显著表达于正常成人睾丸组织及肾癌组织中,但在其他正常组织中未见表达。PRAMEF12在70例肾癌组织中阳性表达率为60%(42/70),并与患者的年龄、性别及病理分期之间无显著统计学意义(P=0.758,P=0.837,P=0.457)。结论 PRAMEF12是一个新的肿瘤睾丸抗原,异常表达于部分肾癌患者,可能促进肾癌的发生与发展。
Objective Tumor cancer-testis antigens (CTAs) are restricted to testicular germ cells and tumor cells and have high immunogenicity. They can stimulate the immune response of tumor patients and are considered as antigen-specific immunotherapy Potential target. This study analyzed and identified whether preferentially expressed antigen of melanoma family member 12 (PRAMEF12) is a new tumor testis antigen and explored its expression in renal cell carcinoma. Methods RT-PCR was used to analyze the expression of PRAMEF12 mRNA in normal adult tissues and renal cell carcinoma tissues. Western Blot and Immunohistochemical Analysis of the Expression of PRAMEF12 Protein in Renal Cell. The relationship between the expression level of PRAMEF12 protein and the clinical features of the cases was analyzed by statistical methods. Results PRAMEF12 was significantly expressed in normal adult testicular and renal cell carcinoma tissues but not in other normal tissues. The positive expression rate of PRAMEF12 in 70 cases of renal cell carcinoma was 60% (42/70), which was not significantly different from the age, sex and pathological stage (P = 0.758, P = 0.837, P = 0.457) . Conclusion PRAMEF12 is a new tumor testis antigen that is abnormally expressed in some patients with renal cell carcinoma and may promote the occurrence and development of renal cell carcinoma.